Cargando…

Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens

OBJECTIVE: Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established. METHODS: Patients with early-stage OC from the National Health Insurance Research database of Taiwan who rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chien-An, Chiang, Chun-Ju, Chen, Yun-Yuan, You, San-Lin, Hsieh, Shu-Feng, Tang, Chao-Hsiun, Cheng, Wen-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709526/ https://www.ncbi.nlm.nih.gov/pubmed/29185274 http://dx.doi.org/10.3802/jgo.2018.29.e16

Ejemplares similares

Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study
por: Huang, Hsin-Ying, et al.
Publicado: (2021)

Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens
por: Lee, Yoo Sung, et al.
Publicado: (2012)

Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
por: Cheng, Min, et al.
Publicado: (2019)

Radiomics signature of computed tomography imaging for prediction of survival and chemotherapeutic benefits in gastric cancer
por: Jiang, Yuming, et al.
Publicado: (2018)

Metabolic interrogation as a tool to optimize chemotherapeutic regimens
por: Sandulache, Vlad C., et al.
Publicado: (2017)

Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan
por: Chiang, Ying-Cheng, et al.
Publicado: (2013)

Alterations in brain neurocircuitry following treatment with the chemotherapeutic agent paclitaxel in rats
por: Ferris, Craig F., et al.
Publicado: (2019)

Chemotherapeutic Agent Paclitaxel Mediates Priming of NLRP3 Inflammasome Activation
por: Son, Seunghwan, et al.
Publicado: (2019)

Analysis of the Efficacy of Multidrug Combination Chemotherapy Regimens for Osteosarcoma and the Management of Chemotherapeutic Reactions
por: Tian, Dawei, et al.
Publicado: (2022)

Bleomycin Containing Chemotherapeutic Regimen Induced Acquired Partial Lipodystrophy
por: Tandon, Vishal R, et al.
Publicado: (2016)

A Systematic Review of Chemotherapeutic Regimens Used in Pancreatic Cancer
por: Awais, Nimra, et al.
Publicado: (2023)

Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer
por: Gao, Xianchun, et al.
Publicado: (2023)

Radiomic signature of( 18)F fluorodeoxyglucose PET/CT for prediction of gastric cancer survival and chemotherapeutic benefits
por: Jiang, Yuming, et al.
Publicado: (2018)

The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment
por: Eckert, Mark A., et al.
Publicado: (2021)

Immunoscore Signature Predicts Postoperative Survival and Adjuvant Chemotherapeutic Benefits in Esophageal Squamous Cell Carcinoma
por: Zhuge, Lingdun, et al.
Publicado: (2020)

Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents
por: Yang, Chen, et al.
Publicado: (2019)

Non-invasive measurement of tumor immune microenvironment and prediction of survival and chemotherapeutic benefits from (18)F fluorodeoxyglucose PET/CT images in gastric cancer
por: Li, Junmeng, et al.
Publicado: (2022)

Colloidal Assemblies Composed of Polymeric Micellar/Emulsified Systems Integrate Cancer Therapy Combining a Tumor-Associated Antigen Vaccine and Chemotherapeutic Regimens
por: Huang, Chiung-Yi, et al.
Publicado: (2021)

Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study
por: Chang, Yen-Hou, et al.
Publicado: (2016)

Chemotherapeutic Effect on Ovarian Stroma and Tumor Cells Which Make Problem in Diagnosis and Staging of Tumor
por: Nasirian, Neda, et al.
Publicado: (2021)

Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors
por: Kim, Daejin, et al.
Publicado: (2010)

Differences of survival benefits brought by various treatments in ovarian cancer patients with different tumor stages
por: He, Tingshan, et al.
Publicado: (2023)

Effect of Gallic acid in potentiating chemotherapeutic effect of Paclitaxel in HeLa cervical cancer cells
por: Aborehab, Nora M., et al.
Publicado: (2019)

Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel
por: Sousa-Pimenta, Mário, et al.
Publicado: (2023)

Liposome-Micelle-Hybrid (LMH) Carriers for Controlled Co-Delivery of 5-FU and Paclitaxel as Chemotherapeutics
por: Hassan, Md. Musfizur, et al.
Publicado: (2023)

Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
por: Lee, Matilda X., et al.
Publicado: (2018)

Benefits of annual chemotherapeutic control of schistosomiasis on the development of protective immunity
por: Chisango, Tawanda J., et al.
Publicado: (2019)

In vitro sensitivity of human ovarian tumours to chemotherapeutic agents.
por: Wilson, A. P., et al.
Publicado: (1981)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Chemotherapeutic Risk lncRNA-PVT1 SNP Sensitizes Metastatic Colorectal Cancer to FOLFOX Regimen
por: Wu, Shenshen, et al.
Publicado: (2022)

NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
por: Saldanha, Elroy, et al.
Publicado: (2022)

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
por: Yardley, Denise A., et al.
Publicado: (2012)

Complete Regression of Primary Cardiac Lymphoma With Dose-Attenuated R-CVP Chemotherapeutic Regimen
por: Mandal, Amit K.J., et al.
Publicado: (2019)

Retracted: Analysis of the Efficacy of Multidrug Combination Chemotherapy Regimens for Osteosarcoma and the Management of Chemotherapeutic Reactions
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer
por: Li, Xiaoguang, et al.
Publicado: (2016)

The cancer chemotherapeutic agent paclitaxel (Taxol) reduces hippocampal neurogenesis via down-regulation of vesicular zinc
por: Lee, Bo Eun, et al.
Publicado: (2017)

Interactions of Some Chemotherapeutic Agents as Epirubicin, Gemcitabine and Paclitaxel in Multicomponent Systems Based on Orange Essential Oil
por: Samide, Adriana, et al.
Publicado: (2021)

Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations
por: Jean, Stephanie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gdl58pd5f08q09ol4gt3d6c4ai